Bortezomib retreatment for relapsed and refractory multiple myeloma in real-world clinical practice.

C, Hulin; la Rubia J, de; MA, Dimopoulos; E, Terpos; E, Katodritou; V, Hungria; Samblanx H, De; AM, Stoppa; J, Aagesen; D, Sargin; A, Sioni; A, Belch; J, Diels; RA, Olie; D Jr, Robinson; A, Potamianou; de Velde H, van; M, Delforge

doi:10.1002/hsr2.104

Public

Bortezomib retreatment for relapsed and refractory multiple myeloma in real-world clinical practice.

Shared by NobleBlocks on Dec 7, 2018 • 12:00 AM UTC

Authors:

Hulin C

de la Rubia J

Dimopoulos MA

Abstract

Aims Studies have shown that bortezomib retreatment is effective in relapsed/refractory multiple myeloma (MM). The observational, prospective electronic VELCADE® OBservational Study (eVOBS) study assessed bortezomib-based therapies for patients with MM in everyday practice. Here, we report on those ...

Subject

Multiple myeloma

Refractory

Real World

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!